Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation?

Basit Öğe Kaydı
dc.authoridAkbulut, Sami/0000-0002-6864-7711
dc.authoridKoc, Cemalettin/0000-0002-5676-6772
dc.authorwosidAkbulut, Sami/L-9568-2014
dc.authorwosidKoc, Cemalettin/B-6430-2018
dc.contributor.authorAkbulut, Sami
dc.contributor.authorKoc, Cemalettin
dc.date.accessioned2024-08-04T20:48:53Z
dc.date.available2024-08-04T20:48:53Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose Hepatocellular carcinoma (HCC) is the second leading cause of cancer deaths and the 7th most common cancer. It has two characteristic features: being advanced stage at diagnosis and association with liver cirrhosis. Liver transplantation (LT) offers the only curative option to treat both components of the disease. The Milan criteria have been extensively used for selecting patients with HCC for LT. However, using Milan criteria, we can only transplant 30% of the patients. The aim of the present review is to evaluate the role of LT in HCC beyond the Milan criteria. Methods We evaluated the studies that have introduced extended criteria to select patients with HCC beyond the Milan criteria. We evaluated the outcomes in terms of disease-free survival rates and HCC recurrences. Results There are patients with tumors that are beyond Milan criteria that could benefit from LT. Selection of these patients has paramount importance in the era of living donor liver transplantation. Current expanded criteria depend on either the bulk of the tumor or the additional surrogate markers of tumor biology such as alpha-fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP). Conclusion There is no ideal marker or an extended criterion for selecting patients with HCC beyond the Milan criteria and it needs further research to find an effective biomarker that has prognostic significance to select patients with advanced tumors.en_US
dc.identifier.doi10.1007/s12029-020-00482-0
dc.identifier.endpage1113en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid32857265en_US
dc.identifier.scopus2-s2.0-85089978777en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1107en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00482-0
dc.identifier.urihttps://hdl.handle.net/11616/99503
dc.identifier.volume51en_US
dc.identifier.wosWOS:000563815100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectMilan criteriaen_US
dc.subjectExtended criteriaen_US
dc.subjectBiomarkersen_US
dc.titleDo We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation?en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu